Roxadustat beyond anemia: A review of its pleiotropic mechanisms and translational potential
Life Sciences, Medicine and Biomedicine · Published 2026-07-31 · DOI 10.28916/lsmb.10.1.2026.260
Free full text
Authors (3)
Qinyun Li, Long Cheng, Nik Nasihah Nik Ramli
Abstract
Roxadustat, a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has been approved for the clinical management of anemia secondary to chronic kidney disease (CKD). Previously published reviews generally focus on single-organ or individual disease manifestations, and a comprehensive systematic overview regarding its potential indications across multiple organ systems remains lacking. Beyond stimulating erythropoiesis, roxadustat triggers extensive transcriptional cascades via systemic stabilization of hypoxia-inducible factor (HIF), thereby exerting pleiotropic pharmacological actions throughout diverse organs. Accumulating preclinical findings and emerging clinical data verify that roxadustat facilitates cardiovascular injury repair, confers neuroprotection, remodels systemic metabolism, maintains iron homeostasis and modulates the tumor microenvironment, conferring promising translational prospects for repurposing in various non-anemic disorders. Nevertheless, widespread activation of the HIF signaling pathway is accompanied by safety concerns including tumor progression promotion, adverse vascular events and endocrine dysfunctions. From a multisystem perspective, this review systematically integrates the molecular mechanisms, preclinical outcomes and translational evidence of roxadustat to fill the existing gaps in available literature. We further highlight that precise patient stratification and standardized long-term safety surveillance are indispensable to fully exploit the therapeutic potential of roxadustat beyond anemia treatment.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Li, Q., Cheng, L., Ramli, N. (2026). Roxadustat beyond anemia: A review of its pleiotropic mechanisms and translational potential. Life Sciences, Medicine and Biomedicine. https://doi.org/10.28916/lsmb.10.1.2026.260
Related articles
- Use of dietary supplement among the elderly in Yangon, Myanmar · Life Sciences, Medicine and Biomedicine · 2022 · Same journal
- Overlapping pathological features of Alzheimer’s and Parkinson’s diseases: Clinical implications and future directions for improving diagnostic precision · Life Sciences, Medicine and Biomedicine · 2026 · Same journal
- Nano-cockle shell powder and alginate as novel injectable bone filler: A preliminary formulation and characterization study · Life Sciences, Medicine and Biomedicine · 2024 · Same journal
- 34th Malaysian Association of Clinical Biochemists Annual Conference in collaboration with 2nd Malaysian Biomedical Science Association Symposium 2024 · Life Sciences, Medicine and Biomedicine · 2024 · Same journal
- A review on betacyanins and anthocyanins as water‑soluble pigments in nanotechnology‑based natural cosmeceutical formulations · Life Sciences, Medicine and Biomedicine · 2026 · Same journal
- Picky eating and its associated factors among children in Asia · Life Sciences, Medicine and Biomedicine · 2025 · Same journal
- Urinary sodium excretion is associated with increased body mass index: A cross-sectional analytical study among adults in Kuala Lumpur, Malaysia · Life Sciences, Medicine and Biomedicine · 2026 · Same journal
- Titanium dioxide nanoparticles induce energy perturbation by stimulating glycolytic metabolic profile in rats · Life Sciences, Medicine and Biomedicine · 2024 · Same journal
- Alteration of pulmonary mitochondrial oxidation status, inflammation, energy metabolizing enzymes, oncogenic and apoptotic markers in mice model of diisononyl phthalate-induced asthma · Life Sciences, Medicine and Biomedicine · 2023 · Same journal
- Perceptions of parents toward online learning among secondary school students during the COVID‑19 pandemic in Malaysia · Life Sciences, Medicine and Biomedicine · 2025 · Same journal